Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYAveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)PREV STORYTurning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock